Acarix Reports Significant Progress Toward Fixed Reimbursement

Malmö, Sweden – Acarix, a global leader in AI- and acoustics-based cardiac diagnostics, is pleased to announce that the company has achieved another milestone on its path toward fixed reimbursement in the U.S. healthcare market.

Three of the five largest payors in the country have removed the “experimental and investigational” designation for CADScor® and lifted prior authorization requirements for reimbursement. While this does not yet constitute fixed reimbursement, it represents a major advancement in the process, where physicians are now seeing consistent payments for usage of CADScor® with these three national payors. 

Datum 2025-08-21, kl 08:30
Källa MFN
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 125 000 sidvisningar och 17 000 unika besökare per månad. Vår discord har 7800 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!